is all in $AAPL $TSLA and $PMCB
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anyway, the S3 just went effective so we might be hearing REAL news soon.
I don't even see that as a group in FB. Not really an expert at navigating FB, but it doesn't show up under closed groups or all groups.
I honestly didn't think posts were capable of moving this stock, but today I saw otherwise.
esusun posted at 11:02 a.m. when $PMCB buy/sell was 175,115 / 85,856.
By close $PMCB buy/sell was 277,832 / 968,246.
I have searched FB and can't find the alleged comments.
Anyone?
Lynn Tilton, CEO of Patriach Partners. SEC's case against Lynn Tilton dismissed
18 Hours Ago | 00:52
The Securities and Exchange Commission's fraud case against investor Lynn Tilton was dismissed, CNBC has confirmed.
Tilton has been fighting a two-year-old SEC administrative case that accused her of misleading investors about the value of loan pools, and collecting $200 million in extra management fees. Tilton's firm, Patriarch Partners, invested in distressed private equity assets, including loans. The case concerned $2.5 billion of loan pools.
The SEC's enforcement division had no comment for CNBC on Wednesday, after the decision by an administrative law judge to dismiss the case. In the decision, the judge said the violations the SEC alleged were "unproven."
"She's been totally vindicated," said Tilton's lawyer, Randy Mastro of Gibson Dunn & Crutcher. "Her reputation has been restored and justice has been done."
There was a hearing last November in the proceeding, but Tilton has been fighting the SEC's internal process as unfair to defendants. She took her arguments to the U.S. Supreme Court, trying to get her case moved to federal court, but the high court denied her petition in May.
In a statement Wednesday, Tilton said, "I am heartened to finally be able to put to rest the rumors and innuendo that have cast a dark shadow on me and my business for so long. Throughout this ordeal, I have worked hard to ensure that my focus on my companies did not waver; without this meritless lawsuit hanging over our heads, however, we can now redouble our efforts to lead the portfolio companies toward growth and prosperity."
-- Robert Frank contributed to this report
https://www.cnbc.com/2017/09/27/sec-drops-fraud-charges-against-investor-lynn-tilton.html
The real difference between NYSE and OTC fraud cases: NYSE CEO's have better lawyers.
SEC's new Cyber Unit
"The Cyber Unit will focus the Enforcement Divisionβs substantial cyber-related expertise on targeting cyber-related misconduct, such as:
Market manipulation schemes involving false information spread through electronic and social media
Hacking to obtain material nonpublic information
Violations involving distributed ledger technology and initial coin offerings
Misconduct perpetrated using the dark web
Intrusions into retail brokerage accounts
Cyber-related threats to trading platforms and other critical market infrastructure
The unit, which has been in the planning stages for months, complements the Chairmanβs initiatives to implement an internal cybersecurity risk profile and create a cybersecurity working group to coordinate information sharing, risk monitoring, and incident response efforts throughout the agency.
βCyber-related threats and misconduct are among the greatest risks facing investors and the securities industry,β said Stephanie Avakian, Co-Director of the SECβs Enforcement Division. βThe Cyber Unit will enhance our ability to detect and investigate cyber threats through increasing expertise in an area of critical national importance.β
Over the past several years, the Enforcement Division has developed substantial expertise in the detection and pursuit of fraudulent conduct in an increasingly technological and data-driven landscape. The Cyber Unit will consolidate and advance these efforts, and include staff from across the Enforcement Division.
Robert A. Cohen has been appointed Chief of the Cyber Unit. Since 2015, he and Joseph Sansone have been Co-Chiefs of the Market Abuse Unit. Mr. Sansone will continue to lead the Market Abuse Unit as its Chief."
https://www.sec.gov/news/press-release/2017-176
Be a real shame if someone reported all the accounts posting bogus info about $PMCB to the new SEC Cyber unit...
Please share with us your source of nonpublic info.
I'm still going with this until I hear otherwise:
http://pharmacyte.com/pharmacyte-biotech-updates-ind-submission-process-in-interview-with-facet-life-sciences/
https://www.barchart.com/stocks/quotes/ACBFF/cheat-sheet
2.2267 1st support
2.2083 2nd support
Auris Medical Announces Transfer to Nasdaq Capital Market
https://finance.yahoo.com/news/auris-medical-announces-transfer-nasdaq-123117030.html
$OTIC has a book value of $4.96 per share according to BarChart:
https://www.barchart.com/stocks/quotes/OTIC/profile
See the Company Profile page, and the box on the right with "OTIC Ratios".
While I've only ever heard of a handful of companies that closed operations and distributed cash to shareholders, this situation does mean that OTIC is undervalued as it's closing price yesterday was $3.35.
On OTIPRIO for Acute otitis externa, $OTIC had a successful Phase 3 in Jan of 2017. PDUFA date for sNDA filing is March 2, 2018.
So, in Q1 2018 IF OTIPRIO is approved, $OTIC should see a nice bump.
In the meantime, I'd expect OTIC to file for Phase 3 on OTO-311 for Tinnitus AND either refile an application for Ménière's disease (based on data review- was failure due to poor trial design?) or to purchase IP from another company and pursue a new pipeline.
Yes, I think producing both a MCB and a WCB must double the time and expense. From the very impatient PMCB shareholder perspective, if the MCB can treat 50,000+ patients, why not just go with that? Well, the answers is after the original MCB is used up, PMCB would have to create a new MCB and then re-file with the FDA. Even if everything was exactly the same, the FDA would still consider it a new, untested biologic that has to go though a new round of testing.
So, from the longer term view, yes, you want a MCB that can produce WCB's that can potentially treat millions of patients. Do it once and do it right. From the viewpoint of any potential partners, because of the 12 year market exclusivity for biologics, you have to have the capability to treat millions and not thousands of patients over that time frame.
Finally, the testing of the MCB to produce a WCB is a double check of the freezing and un-freezing process and further validates the process.
So it's my understanding that $ACBFF now has it's license to sell oils and the reason this is most significant is because you can take excess inventory of dried bud and convert it to oils which has a longer shelf life.
I don't believe Legalization in June/July 2018 is fully priced in because all the details are not yet known.
On this ticker I really like the buildout of Aurora Sky for legalization, the oils license, and the acquisition in Germany.
Thanks!
I have this page bookmarked and I hope one day very soon we will see some updates! : ))))
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=457014
I'm also running out of posts so let me go ahead and do a shameless plug:
For $PMCB DD please take a look at some of these recent posts:
Factual Posts:
Medical and scientific personnel currently associated with $PMCB
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134711479
Principal Investigator will be Dr. Hidalgo, MD, PhD
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134723048
Master Cell Bank being produced by Eurofins
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134794043
Austrianova's IP
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134787469
$PMCB's new corporate law firm
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134622365
$PMCB has four institutional investors with small, "placeholder" positions
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134474894
Recent $PMCB Events
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134528572
Speculative Posts:
Why would a large pharma company want anything to do with $PMCB?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134833898
Speculation regarding the S-3 law firm
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134711413
Pattern related to S-3 Filings and partnerships
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134711743
haven't heard a word from PMCB since February
Feb 12: Comparator Arm announced
Feb 21: TD2 discusses patient enrollment
March 13: Dr. Makowka joins as Senior Strategic Advisor
March 17: KW addresses IND questions
March 22: PMCB files patent for cancer therapy IP
April 19: PMCB wins BIO Conf "2017 Pipelines of Promise Award"
May 2: Mr. Thomas Yuen joins PMCB Board
May 8: IND process update with Facet Life Sciences interview
June 13: BIO Conf
July 10: Dr. Abecassis joins PMCB Board
July 26: Dr. Sher joins PMCB as Chief Medical Officer
http://ir.pharmacytebiotech.com/press-releases
I think you are confusing ECNs with MMs. Multiple bids/offers go to the MMs and only the best are displayed.
I saw Pink's bid because it was the best bid at that time.
From Dick Wolf
Creator of the award winning Law & Order series
A new program with shows ripped from today's headlines
Law & Order SEC Cyber Crimes
DUN DUN!
Excited Young Male Skinny SEC Analyst: We're picking up a coordinated, Level 5 campaign on ticker $PUMP!!!
DUN DUN!
Sarcastic and Sassy SEC IT Expert: Sock puppet accounts with IPs in Russia and China confirmed.
DUN DUN!
Gorgeous Young Female SEC Analyst: My God! Hundreds will lose their lunch money!!! Think. Of. The. Children. (cries)
DUN DUN!
Veteran SEC Assistant Director: OK team, pull it together! Game faces! Grab your reading glasses and calculators. Our private jets leaves in 15!
$SGMO presenting to the Cantor Fitzgerald Global Healthcare Conference TODAY.
IF you have Flash installed you can see the webcast and deck: http://investor.sangamo.com/events/detail/1403/2017-cantor-fitzgerald-global-healthcare-conference
For Hemophilia A, $SGMO has a partnership with $PFE:
Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency
http://investor.sangamo.com/press-releases/detail/365
Three current FDA Phase 1/2 trials, for $SGMO:
MPS I (Scheie, Hurler-Scheie and Hurler syndromes)
MPS II (Hunter syndrome)
Hemophilia B
https://www.biopharmcatalyst.com/company/SGMO
$SGMO is pre-clinical with 3 current Phase 1/2 studies with data due by March 2018.
But the pipeline is very wide and this will be an interesting stock in the 3-5 year time frame.
Congrats to everyone who got aboard this train in the $5 range!!!
http://www.sangamo.com/product-pipeline
HMMJ.CA is just under the IPO price. My guess is if it had done better than the Agro Sphere (spelling?) one would have launched.
Can anyone who knows $OTIC's finances better please chime in.
Balance sheet for 6/30 shows $155,337,000 in liquid assets. OS is 30,303,000. Market cap is currently $100 M.
Book value of OTIC is $155,337,000 / 30,303,000 or $5.13 a share!!
The $155M does not include the value of any IP or goodwill. Am I missing something here?
As of 6/30 $OTIC had $155,337,000 in CASH.
Market Cap is currently $100M. So, it's trading below book value, not including the value of any IP. Strictly cash and Treasuries. Wow.
Biotech investments are not for the impatient! For me, $PMCB is a HOLD.
If you believe in $PMCB and Austrianova's Cell-in-a-Box, you buy some stock and you wait. You don't invest in biotechs on the weekly time frame. Speculative biotech stocks like $PMCB are high risk, high reward. Plenty of other great tickers listed under the Hot! tab for swing and momentum traders.
Do I wish the IND was already filed? Of course!
NYSE CEO fraud giving OTC CEO fraud a run for the money:
Equifax CEO Richard Smith Who Oversaw Breach to Collect $90 Million
http://fortune.com/2017/09/26/equifax-ceo-richard-smith-net-worth/
YSK the FDA approval process for Biologics is different from the regular Drug approval process. In fact, while drugs are approved by the FDA's Center for Drug Evaluation and Research (CDER), new biologics are approved by The Center for Biologics Evaluation and Research (CBER).
https://www.focr.org/fda-regulatory-policy
CDER: https://www.fda.gov/drugs/developmentapprovalprocess/
CBER: https://www.fda.gov/biologicsbloodvaccines/developmentapprovalprocess/
FDA Biologics FAQ: https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/ucm113522.htm
I found these slides (from 2014, so some things may have changed) comparing the different Drug and Biologics approval processes:
https://www.slideshare.net/gas25/usfda-nda-vs-bla
Note slide 39, which indicates that the facility producing the biologics must also be reviewed and approved. I suspect this is one of the reasons $PMCB switched to Eurofins to produce the master and working cell banks. Eurofins surely already has had an FDA Product Standards facilities inspection as it already does work for 9 of the 10 largest pharma companies in the world.
For $PMCB DD please take a look at some of these recent posts:
Factual Posts:
Medical and scientific personnel currently associated with $PMCB
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134711479
Principal Investigator will be Dr. Hidalgo, MD, PhD
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134723048
Master Cell Bank being produced by Eurofins
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134794043
Austrianova's IP
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134787469
$PMCB's new corporate law firm
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134622365
$PMCB has four institutional investors with small, "placeholder" positions
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134474894
Recent $PMCB Events
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134528572
Speculative Posts:
Why would a large pharma company want anything to do with $PMCB?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134833898
Speculation regarding the S-3 law firm
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134711413
Pattern related to S-3 Filings and partnerships
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134711743
Can you talk about the items on the list in relation to PharmaCyteβs progress and what further rate limiting steps are on the path to filing the IND?
Sarah DeMare: βDocumentation of work done on items (a), (b) and (c) and a significant amount of material concerning item (d) have been accumulated to date. As for item (f), publications of Phase 1/2 and Phase 2 trials that were published in scientific journals are βin-house,β as are original clinical reports of those clinical trials. The clinical trial protocol is nearing the βfinalβ stage. Items (h), (i) and (j) will be written by Translational Drug Development (TD2), the Contract Research Organization (CRO) PharmaCyte has retained to conduct the clinical trial in the U.S. and oversee its conduct in Europe by Clinical Network Services (CNS).β
βThe rate limiting step to being able to file the IND and, ultimately, begin the clinical trial is the manufacture of the combination drug product. For live cell-based products, a Master Cell Bank or βMCBβ first needs to be manufactured, characterized, tested and released. The speed at which the MCB can be produced is dependent on several different things. First, is the availability of starting materials. Some starting materials can have a significant lead-time when ordering, and you cannot begin manufacture until you have all your starting materials. Second, is the growth rate of the live cells. Cells grow at different rates. There isnβt much that can be done to speed up that process. Unfortunately, it is not a 1 to 2-day event. β
βAlso, when working with a Contract Manufacturer Organization (CMO) to make your cell bank, some things are out of your control. For example, scheduling. CMOs typically schedule their manufacturing rooms out months in advance for their clients, so sometimes you need to wait in the queue for your turn. In addition, and perhaps most importantly, the MCB needs to be tested to ensure its quality, which is of utmost importance. These tests are also not tests that can always be done quickly. Sterility is a good example. This test is mandatory to ensure the sterility of your MCB and takes approximately 6 weeks to obtain results.β
βThe purpose of creating a MCB is to provide a repository of live cells that are essentially identical to the material tested in clinical trials and throughout the development process. After creating a MCB, a Working Cell Bank or βWCBβ must be manufactured. Creation of a WCB is an important step, as it allows your Master Cell Bank to have a longer useful life.β
βThis is an important point, and itβs worth illustrating. Letβs say you can make 300 vials in your MCB. Letβs also say that each vial of cells can produce enough drug product to treat 100 patients. That would mean you could potentially treat 30,000 patients with the entire MCB. Sounds like a lot, right? Maybe, but this MCB will need to provide cells to patients for years to come. At some point in the future, the MCB will be depleted. This would require another MCB to be produced, and in such a complex system there would be no guarantee that the original cells could be duplicated exactly. In the best case, this means extensive testing would be needed to prove that the new MCB is equivalent to the old MCB.β
βIf those tests reveal differences that could affect efficacy, a new clinical study may be needed to demonstrate that the new MCB is equivalent to the old MCB. There is always the potential that it will not be equivalent. That is the situation the FDA would like to avoid, which is why a Working Cell Bank is needed. To make a WCB, you take one vial of your Master Cell Bank and grow it into more vials to become your Working Cell Bank. So, theoretically, you could get 200 vials of your Working Cell Bank from 1 vial of your Master Cell Bank. Assuming one vial of your WCB still treats 100 patients, you could treat 20,000 patients from only 1 vial of Master Cell Bank. Using this example, a 200-vial Master Cell Bank could treat up to 4 million patients. Compare that to the 30,000 patients you could treat with the entire Master Cell Bank, and you can see that having a WCB allows your MCB to go much further and last much longer.β
βProducing a Working Cell Bank is similar to the Master Cell Bank in that it takes time for the live cells to grow, and you need to test and release the live cells. Sterility testing is still required, and it still takes 6 weeks to perform.β
βFinally, with the Working Cell Bank ready, the drug product can be manufactured, tested and released. The FDA will want to see the test results that demonstrate the quality of the drug product in the IND. So, the IND cannot be filed until the testing of the drug product is completed.β
Kenneth L. Waggoner, age 69
BA Poly Sci, CSU Long Beach, 1970
JD with Honors, Loyola Law, 1973
Senior Partner, Brobeck, Phleger & Harrison, 1986 - 2002
VP and GC, Chevron/Texaco Global Downstream, 2003 - 2005
Private practice?, 2005-?
GC, Trussnet Group Ltd, ?
EVP and GC, Velatel Global, 2009 - 2013
CEO and GC, PharmaCyte, 2013 - present
https://www.linkedin.com/in/kenneth-l-waggoner-08042215
Trussnet was acquired by ChinaTel / Velatel, which went bust trying to run cell phone companies in China and Peru?
So that's where the hate comes from? ChinaTel / Velatel / Trussnet went out of business. So people who hate PMCB today are people who lost money or jobs at ChinaTel / Valatel / Trussnet?
I see a Westmoore ponzi scheme that ensnared ChinaTel, but I don't see anything in the SEC complaint that ChinaTel was at fault or had knowledge. On the contrary, ChinaTel sued Westmoore.
This has been up for a while, at least as an ECN.
Very confusing but they seem to have a trading floor, membership, and to have done 116M or 2.2% of all US trading volume on 9/21 (ARCA, for comparison, is normally 8-10%).
If anyone has access to historic Level 2 data you should see this as IEXG. Maybe check QQQs?
instructions unclear... standing in front of Brotherhood of Electrical Workers office... have asked for Sicilian pizza with capers... getting odd looks... now, they're getting hostile... please send extraction team stat!
It's a dirty, filthy, utterly distasteful yobb, butt I have undertaken it and I will see it through to the end.
I have orders from the KingBit... (a/k/a SWMBO - SheWhoMustBeObeyed) and I'm nott gonna lose this plum yobb as a well-paid (in 'troptions') basher.
Look, man, go down to the local Bashers union hall and sign up for an apprenticeship. Tell the head of the local that you know 1manband and that you're mom is Sicilian - he'll bump you up to the top of the list if you slip him an envelope with $400 cash (in well-worn $20s).
If KingBit... approves ya, sumbuddy will contackt ya. If you don't hear nuttin', don't axe and don't go back to the local. Just move on with your life. Nott everyone can be a made basher. You might be able to join a bash crew for select bash capers and, after earning your bones, you may be tossed a few crypto tokens for yer tip jar if you work good on yobbs. Maybe gett a free case of Dewars every once in awhile or a microwave oven that fell off the truck. Don't ever axe for compensation, or you may wind up in a building foundation or in two 55 gallon drums with concrete dumped in the Schuykill river.
Why would a large pharma company want anything to do with $PMCB?
First, we see many posts that sort of simplify things to "Where is PMCB's cure for pancreatic cancer?"
$PMCB hasn't developed a new drug to combat pancreatic cancer. Instead, it has taken cells that produce an already FDA approved chemotherapy drug, ifosfamide, and encapsulated them using Austranova's IP in cellulose-based capsules that are unique in that they cause no immune response from the body.
Encapsulated cells create what's called a biologic, and in this case trademark protected under the name Cell-in-a-Box or CiaB. CiaB allows for injectable, targeted chemotherapy, versus traditional IV chemotherapy. Because IV chemotherapy is circulated throughout the entire body, it naturally has many horrible side effects.
At this stage of the game $PMCB is offering big pharma a delivery system for already approved drugs. The nice thing about this is prior safety and efficacy studies can be relied upon. The other nice thing is cost. Finding a new drug to treat pancreatic cancer would likely cost between $2-$10 Billion dollars. Instead, we are taking what has been proven to work in the past and making it better. Smaller, better targeted doses.
Better for the patients and better for the company. Better for the patients because of smaller does of, in this case, ifosfamide, which means fewer side effects. Better for the companies, because the new biologic will have market exclusivity for 12 years. Remember, market exclusivity for a brand new drug is generally 5 years.
If you take a look at the long list of chemotherapy drugs owned by a company like J&J, you see names like CAELYX (doxorubicin hydrochloride), which went generic in 2013, and is used to treat cancer of the ovary or breast. This drug is still produced, but as a generic brings in modest revenue.
I have no idea if cells can even be created to produce doxorubicin hydrochloride, but bear with me here. For a relatively modest investment (the millions required for testing, IND submission, phase 2b trial) J&J could end up with a new CiaB biologic to target solid ovary and breast tumors that would have a 12 year market exclusivity.
So, you have that on the one hand and on the other hand the sobering reality that it would require between $2-10 Billion dollars to develop a new drug to target those cancers. $2-10 Billion for a market exclusivity of just 5 years.
J&J has several chemotherapy drugs off exclusivity now and they have more coming off in 2018 and beyond.
IF $PMCB has a successful phase 2b for pancreatic cancer, I strongly believe big pharma will want to try to replicate the success of CiaB and ifosfamide with countless other chemotherapy drugs.
Is that going to happen tomorrow? No. But I believe we are at the cusp of the most important moment in $PMCB's history.
I believe in the science and I believe in the math (that it's more cost effective to pursue new biologics than seek new drugs). Most importantly, I believe in the team KW has assembled, most importantly Dr. Manuel Hidalgo our Principal Investigator and most recently Dr. Sher our new CMO.
"Now I am truly disappointed..."
and you continue to vex me
I'm not saying a fake 8-K would be filed via pdf, I'm saying the most likely way a hacker got access via Edgar is by having a zero day exploit in a pdf file. Doesn't matter if is a primary document. The pdf format was the trojan horse.
Pretty certain they were already scanning for Java code in HTML. That leaves pdf.
Edgar definitely accepts PDF and has for years.
Yes, that would be dramatic and I'm sure that's how it would be portrayed in a Hollywood (Bollywood?) movie!
But as you know alarm bells would go off as the Edgar compliance departments received filing notifications via email and text messages. The security could be halted I suppose, but the IR people could instantly notify people it was a fake 8-K.
I dunno. They could easily trace the subsequent orders to at least the broker.
Seems to me a much smarter way to make money is by front running the news in small trades. Smaller reward, but far less risky. The fact that the SEC only discovered the hack afterwards leads me to believe this crew went the low risk route.
The problem with EDGAR is by it's nature it accepts HTML code and PDFs. I'm sure it has the latest wonderful anti-virus scanning systems, but anytime you allow someone to submit a document into your system you're going to be vulnerable to the worst zero day exploits.
If these hackers were smart they were searching for Confidential Treatment Requests and Draft (non-public) Registration Statements.
Bud Fox version 3.0?
I have filed a whistleblower complaint, I just never thought I would actually see any reward. I'd imagine it takes years for rewards to be awarded. Is that your experience?
If you want a very sobering review of the state of R&D for new drugs in the US please read this report:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847363/
Highlights:
...According to Paul et al., drug R&D (across all therapeutic areas) takes on average 14 years. Discovery research lasts for 4.5 years, preclinical testing continues for 1 year, the three clinical development phases take 1.5, 2.5 and 2.5 years, respectively, and the phase from submission to launch requires another 18 months....
In consequence and following the argumentation of Harper [30] the historical calculation of approximately USD 1 billion per approved drug needs to be corrected to an amount of more than USD 3 billion (see Table 1). In detail, Boehringer Ingelheim, Bristol-Myers Squibb, Takeda and GSK all spent USD 3β4 billion per NME, while Amgen, Novartis, AstraZeneca, Pfizer, Merck & Co., Sanofi and Roche each invested up to USD 8 billion per new drug approved by the FDA. And Eli Lilly and Abbott/AbbVie invested even more than USD 10 billion per NME (2006β2014)βan amount of money that at least for some pharmaceutical companies put a question mark on the sustainability of their R&D models.
Sign me up!
No, in all seriousness, if there is a way to profit from uncovering frauds please let me know where to sign up.
I don't short stocks on general principal. But I have some detective skills. More importantly, I know someone who is a CFA who can spot complex accounting shenanigans in milliseconds. Where do we sign up?
I'm not the type to don tin foil hats, but I have to say I think you might be onto something there.
I ventured onto other well known sites for PMCB info and I got a swift and coordinated virtual beatdown for stating anything positive about PMBC. Like 20 against 1.
iHub has the most balanced discussion of this ticker. Everywhere else it is one sided.
I don't know exactly what that means, but it is a fact.
Absolutely. KW has said repeatedly they get one chance and it has to be perfect.
Google "failed FDA Phase III 3".
Here, I'll save you 3 seconds: http://www.genengnews.com/the-lists/unlucky-13-top-clinical-trial-failures-of-2016/77900787
Notice the phrase "missed primary end points" in every case. So you have drugs that are safe and effective - that actually work - but because of poor trial design failed to get FDA approval.
Result? Millions of dollars for clinical trials wasted and market caps destroyed.